Back to top
more

Revance Therapeutics (RVNC)

(Delayed Data from NSDQ)

$3.70 USD

3.70
13,065,655

-2.08 (-35.99%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $3.71 +0.01 (0.27%) 5:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q4 Earnings Expected to Decline

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 32.11% and 0.13%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

What Makes Revance Therapeutics, Inc. (RVNC) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Revance Therapeutics, Inc. (RVNC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Revance Therapeutics, Inc. (RVNC) Soars 8.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -37.65% and 0.90%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Athenex (ATNX) delivered earnings and revenue surprises of 12.50% and 16.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Allogene Therapeutics (ALLO) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 6.45% and 45.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

HOOKIPA Pharma Inc. (HOOK) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

HOOKIPA Pharma Inc. (HOOK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

by Zacks Equity Research

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 3.30% and 2.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -20.18% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of -3.30% and 7.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Twist Bioscience (TWST) delivered earnings and revenue surprises of 1.59% and 5.28%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 8.7% Jump Turn into More Strength?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 4.35% and -1.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Revance Therapeutics (RVNC) Ahead of Earnings?

by Zacks Equity Research

Revance Therapeutics (RVNC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 6.14% and 12.73%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Revance Therapeutics, Inc. (RVNC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revance Therapeutics, Inc. (RVNC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) delivered earnings and revenue surprises of 9.24% and 6.89%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Revance Therapeutics, Inc. (RVNC) Q1 Earnings Expected to Decline

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Revance Therapeutics, Inc. (RVNC): Can Its 5.4% Jump Turn into More Strength?

by Zacks Equity Research

Revance Therapeutics, Inc. (RVNC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.